Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice

Area of Science:

• Gene Therapy
• Hematology
• Oncology

Background:

• Integrative viral vectors (γ-retroviruses, lentiviruses) enable efficient gene transfer into hematopoietic stem progenitor cells for treating genetic blood disorders.
• Clinical trials using these vectors have shown success, but vector integration has led to oncogenesis via insertional mutagenesis, raising safety concerns.
• Reassessing the safety of gene transfer systems is critical for advancing gene therapy.

Purpose of the Study:

• To describe methodologies for evaluating the genotoxicity risk associated with vector integration.
• To utilize a preclinical murine model for a detailed understanding of factors influencing insertional mutagenesis.
• To enhance the safety of gene transfer systems in gene therapy applications.

Main Methods:

• Development of a murine in vivo genotoxicity assay.
• Transduction of hematopoietic stem and progenitor cells using integrative viral vectors.
• Transplantation of transduced cells into conditioned recipients to assess long-term effects.

Main Results:

• The study outlines a sensitive preclinical model for vector genotoxicity assessment.
• Methodologies are presented to analyze the risk of insertional mutagenesis.
• The model allows for the study of factors modulating mutagenesis risk in hematopoietic stem and progenitor cells.

Conclusions:

• Preclinical models are essential for understanding and mitigating the risks of insertional mutagenesis in gene therapy.
• The described murine assay provides a valuable tool for evaluating vector safety.
• This research contributes to the development of safer gene transfer strategies for treating genetic diseases.